Creative Financial Designs Inc. ADV Increases Stake in Amgen Inc. (NASDAQ:AMGN)

Creative Financial Designs Inc. ADV grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,300 shares of the medical research company’s stock after buying an additional 151 shares during the quarter. Creative Financial Designs Inc. ADV’s holdings in Amgen were worth $1,381,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Robinson Smith Wealth Advisors LLC grew its stake in shares of Amgen by 8.8% during the 4th quarter. Robinson Smith Wealth Advisors LLC now owns 805 shares of the medical research company’s stock worth $210,000 after purchasing an additional 65 shares during the period. Signature Wealth Management Group grew its stake in shares of Amgen by 126.2% during the 4th quarter. Signature Wealth Management Group now owns 1,796 shares of the medical research company’s stock worth $468,000 after purchasing an additional 1,002 shares during the period. First National Advisers LLC grew its stake in shares of Amgen by 1.6% during the 4th quarter. First National Advisers LLC now owns 18,333 shares of the medical research company’s stock worth $4,778,000 after purchasing an additional 288 shares during the period. GWN Securities Inc. acquired a new position in shares of Amgen during the 4th quarter worth $659,000. Finally, Gallacher Capital Management LLC grew its stake in shares of Amgen by 12.4% during the 4th quarter. Gallacher Capital Management LLC now owns 1,115 shares of the medical research company’s stock worth $291,000 after purchasing an additional 123 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 1.1 %

NASDAQ AMGN opened at $317.17 on Tuesday. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company’s 50 day moving average price is $292.99 and its 200 day moving average price is $299.02. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market capitalization of $170.39 billion, a price-to-earnings ratio of 42.01, a PEG ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.00%. Amgen’s payout ratio is 126.09%.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 over the last 90 days. 0.69% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on AMGN shares. Redburn Partners lowered their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Wells Fargo & Company reissued an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research note on Friday, January 24th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $314.04.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.